Supply of oncology medicines

Summary

The tender concerns the supply of oncology medicines under a framework agreement. The contracting authority will place subsequent contracts according to its needs and available funding. The procurement is divided into 48 lots covering medicines such as aflibercept, atezolizumab, bevacizumab, carboplatin, cisplatin, pembrolizumab, trastuzumab and other antineoplastic products. Minimum and maximum framework quantities are specified for each product; the estimated value is RON 24,107,837.76. The deadline for tenders is 21 September 2026. Electronic invoicing or another electronic process is required. The supplier must hold the required registrations and medicinal-product authorisations and submit the required declarations and evidence.